ORKA Oruka Therapeutics, Inc.
ORKA Oruka Therapeutics, Inc.
Healthcare · Biotechnology
Market read
POC $68.49 · VWAP $67.53 · +18.7% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, COO + 3 others sold $3.1M, Sep 15–21
Coverage
1 watchlist
ORKA Price Structure
Loading timeframes…
Peers
Every watchlist ORKA belongs to, members best 30-day change first — ORKA highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Oruka Therapeutics furnished its earnings release to the SEC on August 10, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. No figures from these filings are recorded here.
full note →Against street estimates
How ORKA's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
ORKA research tape
18 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.